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Human  -defensin  3 (HBD3)  is  a small,  well-characterized  peptide  in mucosal  secretions  with  broad
antimicrobial  activities  and  diverse  innate  immune  functions.  Among  these  functions  is  the  ability  of
HBD3  to bind  to antigens.  In  this  study,  we hypothesize  that  HBD3  binds  to  the  allergen  Bla  g2 from  the
German  cockroach  (Blattella  germanica).  The  ability  of  HBD1  (used  as  a control  -defensin)  and  HBD3
to  bind  to Bla  g2 and  human  serum  albumin  (HSA,  used  as  a control  ligand)  was  assessed  using the
SensíQ  Pioneer  surface  plasmon  resonance  (SPR)  spectroscopy  biosensor  system.  HBD1  was  observed  touman -defensin
BD3
llergen
la  g2
urface plasmon resonance spectroscopy
bind  weakly  to Bla  g2,  while  HBD3  demonstrated  a stronger  afﬁnity  for the allergen.  HBD3  was  assessed
under  two  buffer  conditions  using  0.15  M and  0.3 M NaCl  to  control  the  electrostatic  attraction  of  the
peptide  to  the chip  surface.  The  apparent  KD of  HBD3  binding  Bla  g2 was  5.9 ±  2.1  M and  for  binding
HSA was  4.2  ± 0.7  M, respectively.  Thus,  HBD3,  found  in  mucosal  secretions  has  the  ability  to bind  to
allergens  like Bla  g2 possibly  by  electrostatic  interaction,  and may  alter  the  ability  of  Bla  g2 to induce
localized  allergic  and/or  inﬂammatory  mucosal  responses.
© 2014  The  Authors.  Published  by Elsevier  Inc.  Open access under CC BY-NC-ND license.. Introduction
Allergens are exogenous antigens from a variety of environmen-
al sources capable of inducing allergic responses, hypersensitiv-
ties, and asthma in children upon topical, mucosal, or systemic
xposure. These include airborne indoor allergens from pets, house
ust mites, and cockroaches [1,6]. Bla g2 from the German cock-
oach (Blattella germanica) is among these allergens and thought to
e an important risk factor in the development and/or exacerbation
f atopic asthma [6,9]. Bla g2 is detected in 87–93% of air samples
n the bedroom and kitchen often in concentrations of Bla g2 that
pproach the threshold for sensitization in homes of children with
sthma [6]. Exposure to 10−1 to 10−4g/ml Bla g2 induces pos-
tive reactions on cockroach-allergic patients [19]. Furthermore,
∗ Corresponding author at: Dows Institute for Dental Research, College of Den-
istry,  The University of Iowa, Iowa City, IA 52242, USA. Tel.: +1 319 335 8077.
E-mail address: kim-brogden@uiowa.edu (K.A. Brogden).
196-9781 © 2014 The Authors. Published by Elsevier Inc. 
ttp://dx.doi.org/10.1016/j.peptides.2014.01.017
Open access under CC BY-NC-ND simultaneous exposure to cockroach allergen and other environ-
mental antigens, like endotoxin, can exacerbate the pulmonary
response [14].
While  many of the underlying mechanisms of Bla g2-induced
allergy and hypersensitivity are becoming clearer [9], little is
known about the interaction between innate immune molecules,
like human -defensins (HBDs), and Bla g2. HBDs are present
in oral and respiratory tissues and secretions [4,10,11] and thus
are ideally positioned to interact with allergens. HBDs are small,
host-derived peptides with innate and adaptive immune functions
[8,15,20,23]. They have direct antimicrobial activity against bacte-
ria, fungi, and some enveloped viruses; chemoattract phagocytic
and mast cells; induce inﬂammatory mediators; regulate the func-
tions of phagocytes and the complement system; and enhance
adaptive immune responses to co-administered antigens. HBDs
bind to microbial antigens, which may  facilitate receptor-mediated
internalization of the antigen to immature dendritic cells [23] or
attenuate antigen-induced pro-inﬂammatory cytokine responses
[12,18].In our recent work, we have observed that HBD1, HBD3, and
histatin 5 speciﬁcally bind to immobilized adhesins from the peri-
odontal pathogen Porphyromonas gingivalis [2,5,18]. This led us
to hypothesize that HBD1 and HBD3 will also bind similarly to
license.
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mig. 1. SensíQ Pioneer Sensograms of HBD1 and HBD3 binding to immobilized Bla 
n  0.15 M NaCl and (B) the corresponding dose response; (C) HBD3 binding to Bla g
2  in 0.3 M NaCl and (F) the corresponding dose response.
llergens like Bla g2. In this short communication, we report that
BD3 binds via electrostatic interactions, rather than speciﬁc bind-
ng domains, to immobilized Bla g2.
. Methods
.1. Reagents
Bla  g2 (Indoor Biotechnologies, Charlottesville, VA, USA) was
uspended in 10.0 mM sodium acetate, pH 5.0 (immobilization
uffer) and used as the immobilized ligand in SPR spectroscopy.HBD1  and HBD3 (PeproTech, Inc., Rocky Hill, NJ) were sus-
ended in 10.0 mM  HEPES, pH 7.4 containing 0.15 M NaCl, 3.0 mM
DTA, and 0.005% surfactant P20 (HBS-EP buffer) and used as the
obile analytes in SPR spectroscopy.m the German cockroach (Blattella germanica) showing (A) HBD1 binding to Bla g2
.15 M NaCl and (D) the corresponding dose response; and (E) HBD3 binding to Bla
2.2.  SPR spectroscopy
All  SPR measurements were performed with the SensíQ Pioneer
biosensor system at a controlled temperature of 25 ◦C as recently
described [2]. Running buffer for experiments contained 10.0 mM
HEPES, pH 7.4, 0.15 M NaCl, 3.4 mM EDTA, 0.005% (w/w) Tween-
20, and 1.0 mg/mL  CM-Dextran unless otherwise speciﬁed. A
COOH2 sensor chip (SensíQ Technologies) was used for the peptide
assays.
The COOH2 sensor chip was  installed and conditioned accord-
ing to manufacturer’s protocol. Bla g2 and human serum albumin
(HSA), used as a protein control, were each immobilized to differ-
ent ﬂow channels (FC) using a standard amine coupling method.
The method involved activation by injecting 20.0 mM EDC with
5.0 mM NHS followed by an injection of 25.0 g/mL protein solu-
tion in 10.0 mM sodium acetate buffer (pH 4.3 for Bla g2 and
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Fig. 2. SensíQ Pioneer Sensograms of HBD1 and HBD3 binding to immobilized human serum albumin (HSA) showing (A) HBD1 binding to HSA in 0.15 M NaCl and (B) the
corresponding dose response; (C) HBD3 binding to HSA in 0.15 M NaCl and (D) the corresponding dose response; and (E) HBD3 binding to HSA in 0.3 M NaCl and (F) the
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H 5.0 for HSA). Activated surfaces were capped by injecting
.0 M ethanolamine pH 7.5 for 3 min. FC2 was left unmodiﬁed
o serve as a reference for non-speciﬁc binding to the surface
hemistry.
Dilution series of HBD1 and HBD3 peptides was prepared in run-
ing buffer including concentrations: 25.4, 12.7, 6.4, 3.2, 1.6, 0.8 M
nd a buffer blank. Each solution was injected over Pioneer’s three
C for 2.5 min  contact time and the dissociation of bound peptide
as observed under buffer ﬂow for 3 min.
Regeneration of the immobilized Bla g2 was performed by
njecting 2.0 M NaCl for 1 min  after each HBD injection. The HBD
amples were tested in triplicate and the order of testing was  ran-
omized.
A third assay was performed as described above where the HBD3
eptide was prepared in a similar dilution series in running bufferwith  0.3 M NaCl. The running buffer for the instrument was  also
modiﬁed to contain 0.3 M NaCl. The peptide samples were tested
as described above.
2.3.  Analysis
SPR response curves from the true reference channel (FC2) were
subtracted from the Bla g2 (FC1) and HSA (FC3) channel curves.
Buffer blank curves were then averaged and subtracted from the
HBD curves. Dose–response plots were constructed by plotting the
equilibrium response reached during sample injection vs. the pep-
tide concentration. The “one site-total” model was ﬁt to the data to
determine maximum response (Rmax) and KD for each assay with a
term for linear non-speciﬁc binding (Y = Rmax × X/(KD + X) + NS × X.
NS is the slope of the linear non-speciﬁc binding component). The
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BD1 interactions demonstrated a very weak afﬁnity and due to
he low concentrations tested, the KD could not be estimated.
.  Results
HBD1 demonstrated a very weak afﬁnity for Bla g2, which
as not quantiﬁed at the concentrations of peptide tested in this
ssay (Fig. 1A and B). HBD3 was observed to bind with a stronger
fﬁnity for Bla g2 (Fig. 1C–F). HBD3 was also observed to bind non-
peciﬁcally to the reference channel and as a result an additional
ssay was performed where the NaCl concentration was  increased
o reduce this artifact. This non-speciﬁc binding was hypothesized
o be due to the peptide’s electropositive nature in neutral buffer
onditions. The difference in binding response is primarily due to
he reduction in nonspeciﬁc binding to the reference channel in the
.3 M NaCl assay (Fig. 1C vs. E). We  observed that when 2.0 M NaCl
as injected over a channel with bound HBD3 (Bla g2 or reference
hannel) the majority of bound peptide was eluted which indicates
hat HBD3 binding to Bla g2 is mostly ionic in nature.
The binding curves were analyzed assuming the injections had
eached steady state. Since most of the curves were at equilibrium
his is considered an acceptable approximation although longer
njection times will likely return a more accurate KD value. The
pparent KD value for HBD3 binding Bla g2 was 5.9 ± 2.1 M (0.3 M
aCl, Fig. 1F). The appearance of the HBD3 binding responses sug-
ests that the peptide is binding Bla g2 in a heterogeneous manner.
he inclusion of a non-speciﬁc binding term should better analyse
he speciﬁc binding between HBD3 and Bla g2. For the ∼780 RU of
mmobilized Bla g2 we would expect ∼107 RU of peptide binding
t maximum (for a 1:1 interaction) and the estimated Rmax from
he model ﬁt was  87 RU. This supports the hypothesis that the non-
peciﬁc term in the model accounted for linear non-speciﬁc binding
nd accurately characterized the speciﬁc interaction.
An additional control was included to test the binding of the HBD
eptides to HSA (Fig. 2). HSA is a common control protein so it was
sed to demonstrate potential non-speciﬁc protein binding. Similar
quilibrium KD values of HBD binding to HSA, as with Bla g2, were
bserved. The apparent KD for HBD3 binding HSA was 4.2 ± 0.7 M
0.3 M NaCl, Fig. 2F).
. Discussion
HBD1, HBD2, and HBD3 are all known to bind with dif-
erent afﬁnities to a variety of microbial and viral antigens
5,7,13,16–18,21]. Recently, we observed that HBD1, HBD3, and
istatin 5 bind speciﬁcally to immobilized P. gingivalis hemagglu-
inin B (HagB) [2]. Binding occurred in very speciﬁc domains on a
odeled HagB molecule. This led us to hypothesize that HBD1 and
BD3 would also bind similarly to Bla g2. In this short communi-
ation, we report that HBD1 and HBD3 bind to both immobilized
la g2 and HSA. The exact mechanism for the binding of HBDs to
la g2 is not readily known but is likely related to the unique prop-
rties of these defensins and the composition of Bla g2 allergen. It
ould be a non-speciﬁc binding based on electrostatic interactions
etween the defensin analyte and the immobilized adhesin ligand.
inding was inﬂuenced by the NaCl concentrations and occurred
ore readily in 0.15 M NaCl than 0.3 M NaCl conditions. HBD1 has
 net ±3 charge and HBD3 has a net ±11 charge. Electrostatic inter-
ctions were thought to play a role on our results. It is also possible
hat there may  be defensin-speciﬁc binding domains on this aller-
en that favors higher afﬁnity binding of one defensin over another
efensin. This remains to be determined.
HBDs are expressed throughout the oronasal cavity and respira-
ory system [4,10,11] and may  serve to protect these tissues from
llergen exposure. Although early in this concept, it is temptings 53 (2014) 265–269
to  speculate that polymorphisms in defensins or differences in
copy number of defensins in some individuals may  decrease the
ability of defensins to protect mucosal sites from allergen expo-
sure and may  increase the susceptibility of those individuals to
inﬂammation. Copy number polymorphisms and expression level
variations of -defensins [22] may  lead to different defensin pro-
ﬁles. Speciﬁcally for HBD3, the three-copy number variant was
the most frequent genotype occurring in 65.9% of 44 subjects
followed by the two-copy number variant in 30.5% of 44 sub-
jects and the four-copy number variant in 13.6% of 44 subjects
[3]. Furthermore, there are numerous reports that HBD expres-
sion and production are down regulated in individuals with
allergies.
Whether the binding of defensins to cockroach allergen Bla g2
attenuates its ability to induce localized allergic and/or inﬂam-
matory responses is not yet known. There is a good chance this
may occur. Recently, HBD3 was found to attenuate chemokine and
proinﬂammatory responses in dendritic cells treated with recom-
binant HagB from P. gingivalis strain 381 [12,18].
5. Conclusions
The binding of HBD1 and HBD3 to immobilized Bla g2 was  char-
acterized with the SensíQ Pioneer SPR biosensor system. HBD1
was observed to bind weakly to Bla g2 and the afﬁnity constant
was undetermined due to low analyte concentrations being used.
The binding of HBD3 to immobilized Bla g2 was tested at 0.15 M
and 0.3 M NaCl concentrations. Increased salt content sufﬁciently
reduced non-speciﬁc binding to the reference channel to improve
the signal of HBD3 binding the protein channels. The apparent KD
of HBD3 binding Bla g2 was 5.9 ± 2.1 M and for binding HSA was
4.2 ± 0.7 M,  respectively. Both HBD1 and HBD3 bound to immobi-
lized HSA similar to Bla g2 in terms of absolute response and kinetic
shape of binding.
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